Traynor Capital Management Inc. Boosts Holdings in Gilead Sciences, Inc. (GILD)

Traynor Capital Management Inc. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,290 shares of the biopharmaceutical company’s stock after buying an additional 3,210 shares during the period. Gilead Sciences accounts for about 1.1% of Traynor Capital Management Inc.’s portfolio, making the stock its 21st largest holding. Traynor Capital Management Inc.’s holdings in Gilead Sciences were worth $2,289,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Vicus Capital increased its stake in Gilead Sciences by 31.5% during the 3rd quarter. Vicus Capital now owns 11,496 shares of the biopharmaceutical company’s stock worth $931,000 after buying an additional 2,751 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new stake in Gilead Sciences during the 3rd quarter worth approximately $17,967,000. Callahan Advisors LLC increased its stake in Gilead Sciences by 8.8% during the 3rd quarter. Callahan Advisors LLC now owns 90,056 shares of the biopharmaceutical company’s stock worth $7,296,000 after buying an additional 7,297 shares in the last quarter. BARING ASSET MANAGEMENT Ltd purchased a new stake in Gilead Sciences during the 3rd quarter worth approximately $1,890,000. Finally, Palisade Asset Management LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth approximately $227,000. Institutional investors own 75.94% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $72.98 on Thursday. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The company has a market capitalization of $95,310.00, a P/E ratio of 8.30, a P/E/G ratio of -1.22 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same period in the prior year, the firm posted $2.75 earnings per share. The firm’s quarterly revenue was down 13.2% on a year-over-year basis. equities analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.85%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.66%.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.56, for a total transaction of $6,054,372.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The disclosure for this sale can be found here. Insiders sold 494,999 shares of company stock worth $37,404,139 over the last quarter. 1.30% of the stock is currently owned by insiders.

GILD has been the topic of several recent research reports. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Deutsche Bank restated a “buy” rating and set a $81.00 target price on shares of Gilead Sciences in a report on Thursday, August 31st. Argus upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a report on Thursday, August 31st. Berenberg Bank restated a “buy” rating and set a $96.00 target price (up from $86.00) on shares of Gilead Sciences in a report on Wednesday, September 6th. Finally, Vetr upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 target price on the stock in a report on Wednesday, September 6th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $85.03.

WARNING: “Traynor Capital Management Inc. Boosts Holdings in Gilead Sciences, Inc. (GILD)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/28/traynor-capital-management-inc-boosts-holdings-in-gilead-sciences-inc-gild.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

What are top analysts saying about Gilead Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Gilead Sciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit